ADVENTRX Pharmaceuticals, Inc. (Form: 8-K)  

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   June 30, 2010

ADVENTRX Pharmaceuticals, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 001-32157 84-1318182
_____________________
(State or other jurisdiction 		_____________
(Commission 		______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
6725 Mesa Ridge Road, Suite 100, San Diego, California   92121
_________________________________
(Address of principal executive offices) 		  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   858-552-0866

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 5.07 Submission of Matters to a Vote of Security Holders.

The annual meeting of stockholders of ADVENTRX Pharmaceuticals, Inc. (the “Company”) was held on June 30, 2010. The final voting results on each of the matters submitted to a vote of the Company’s stockholders were as follows:

1.   The stockholders elected each of the five nominees to the Company’s board of directors, each to serve until the Company’s 2011 annual meeting of stockholders and until their respective successors are elected and qualified, as follows:
                                 
Nominee
   For   Against   Abstain   Broker Non-Votes
Michael M. Goldberg
     1,413,058       157,645       20,924       7,853,454  
Odysseas D. Kostas
     1,411,768       159,953       19,907       7,853,453  
Jack Lief
     1,409,903       161,308       20,416       7,853,454  
Mark J. Pykett
     1,353,926       216,758       20,944       7,853,453  
Eric K. Rowinsky
     1,411,289       161,177       19,161       7,853,454  

2.   The stockholders ratified the appointment of J.H. Cohn LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2010 as follows:
                 
For
  Against   Abstain
8,945,881
    410,635       88,565  

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    ADVENTRX Pharmaceuticals, Inc.
          
July 2, 2010   By:   /s/ Patrick Keran
       
        Name: Patrick Keran
        Title: President and Chief Operating Officer